Codiak Bio Sciences, Inc. CDAK
We take great care to ensure that the data presented and summarized in this overview for Codiak BioSciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDAK
View allLatest Institutional Activity in CDAK
Top Purchases
Top Sells
About CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at CDAK
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2023
|
Yalonda Howze |
SELL
Open market or private sale
|
Direct |
1,628
-17.92%
|
$0
$0.2 P/Share
|
|
Mar 29
2023
|
Sriram Sathyanarayanan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,762
-100.0%
|
$0
$0.17 P/Share
|
|
Mar 29
2023
|
Nicole Barna |
SELL
Open market or private sale
|
Direct |
7,305
-36.35%
|
$0
$0.17 P/Share
|
|
Mar 28
2023
|
Douglas E Williams President & CEO |
SELL
Open market or private sale
|
Direct |
41,667
-84.48%
|
$0
$0.18 P/Share
|
|
Mar 28
2023
|
Linda Bain Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,412
-100.0%
|
$0
$0.17 P/Share
|
|
Mar 28
2023
|
Konstantin Konstantinov Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
9,364
-89.68%
|
$0
$0.2 P/Share
|
|
Feb 17
2023
|
Yalonda Howze |
SELL
Open market or private sale
|
Direct |
1,603
-15.0%
|
$0
$0.59 P/Share
|
|
Feb 17
2023
|
Nicole Barna |
SELL
Open market or private sale
|
Direct |
1,274
-9.49%
|
$0
$0.59 P/Share
|
|
Feb 17
2023
|
Sriram Sathyanarayanan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,407
-16.99%
|
$0
$0.59 P/Share
|
|
Feb 17
2023
|
Konstantin Konstantinov Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
1,391
-15.77%
|
$0
$0.59 P/Share
|
|
Feb 17
2023
|
Douglas E Williams President & CEO |
SELL
Open market or private sale
|
Direct |
7,681
-13.47%
|
$0
$0.59 P/Share
|
|
Feb 17
2023
|
Linda Bain Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,570
-16.08%
|
$0
$0.59 P/Share
|
|
Feb 16
2023
|
Kyriazi Theo Melas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+36.31%
|
-
|
|
Feb 16
2023
|
Yalonda Howze |
BUY
Exercise of conversion of derivative security
|
Direct |
4,856
+31.24%
|
-
|
|
Feb 16
2023
|
Nicole Barna |
BUY
Exercise of conversion of derivative security
|
Direct |
3,150
+19.0%
|
-
|
|
Feb 16
2023
|
Charles L Cooney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+50.0%
|
-
|
|
Feb 16
2023
|
Steven Gillis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+50.0%
|
-
|
|
Feb 16
2023
|
Sriram Sathyanarayanan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,350
+34.16%
|
-
|
|
Feb 16
2023
|
Jason Haddock Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,750
+50.0%
|
-
|
|
Feb 16
2023
|
Karen Bernstein Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
8,750
+50.0%
|
-
|